The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Efficacy of antidepressants for depression in Alzheimer's disease: systematic review and meta-analysis
Open accessAbstract
BACKGROUND: Depression is common in people with Alzheimer's disease (AD) affecting overall outcomes and decreasing quality of life. Although depression in AD is primarily treated with antidepressants, there are few randomized controlled trials (RCTs) assessing efficacy and results have been conflicting. OBJECTIVES: To systematically review evidence on efficacy of antidepressant treatments for depression in AD. METHODS: Systematic review and meta-analysis of double blind RCTs comparing antidepressants versus placebo for depression in AD. We searched MEDLINE, CINAHL, EMBASE, PsycINFO, the Cochrane Controlled Trials Register and on line national and international registers. Primary outcomes were treatment response and depressive symptoms. Secondary outcomes were cognition, acceptability, and tolerability. Risk of bias was also assessed. RESULTS: Seven studies met inclusion criteria. Three compared sertraline with placebo; one compared both sertraline and mirtazapine to placebo; imipramine, fluoxetine, and clomipramine were evaluated in one study each. In terms of response to treatment (6 studies, 297 patients treated with antidepressants and 223 with placebo), no statistically significant difference between antidepressants and placebo was found (odds ratio (OR) 1.95, 95% CI 0.97-3.92). We found no significant drug-placebo difference for depressive symptoms (5 studies, 311 patients, SMD -0.13; 95% CI -0.49 to 0.24). Overall quality of the evidence was moderate because of methodological limitations in studies and the small number of trials. CONCLUSION: Despite the importance of depression in people with AD, few RCTs are available on efficacy of antidepressants, limiting clear conclusions of their potential role. There is a need for further high quality RCTs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Limited information is available on the efficacy of antidepressants amongst older people with cognitive impairment and dementia (Boyce 2012;Nelson 2011;Orgeta 2017), which is problematic given the high prevalence of these conditions in the LTC population.”
From Psychological therapies for depression in older adults residing in long-term care settings (2024) · cites this paper as Orgeta 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Neuropsychiatric symptoms are common and often clustered in people with dementia.”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [210]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients suffering from AD are more prone to comorbid depression [40, 41]”
From APOE4 genotype exacerbates the depression-like behavior of mice during aging through ATP decline (2021) · cites this paper as [41]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These symptoms might precede dementia and are associated with tau and amyloid neuropathology.210”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [210]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“We used the GRADE approach [41] to summarize overall quality of evidence.”
MethodCognitive Stimulation in Patients with Dementia: Randomized Controlled Trial
Mapelli, D., Di Rosa, E., Nocita, R., & Sava, D. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353457 · Cited by 3,453
Cornell scale for depression in dementia
Alexopoulos, G. S., Abrams, R. C., Young, R. C., & Shamoian, C. A. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90038-8 · Cited by 2,678
Assessment and management of behavioral and psychological symptoms of dementia
Kales, H. C., Gitlin, L. N., & Lyketsos, C. G. (2015) · BMJ · doi:10.1136/bmj.h369 · Cited by 1,247 · cited 1×
“cognitive impairment is the hallmark of the illness, neuropsychiatric symptoms affect almost all patients and are persistent [3, 4].”
BackgroundPredictors of nursing home admission for persons with dementia
Gaugler, J. E., Yu, F., Krichbaum, K., & Wyman, J. F. (2009) · Medical Care · doi:10.1097/mlr.0b013e31818457ce · Cited by 617
Effect of Citalopram on Agitation in Alzheimer Disease: The CitAD Randomized Clinical Trial
Porsteinsson, A. P., Drye, L. T., Pollock, B. G., Devanand, D. P., Frangakis, C., Ismail, Z., Marano, C., Meinert, C. L., Mintzer, J. E., Munro, C. A., et al. (2014) · JAMA · doi:10.1001/jama.2014.93 · Cited by 572
Banerjee, S., Hellier, J., Dewey, M., Romeo, R., Ballard, C., Baldwin, R., Bentham, P., Fox, C., Holmes, C., Katona, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60830-1 · Cited by 532
Lyketsos, C. G., DelCampo, L., Steinberg, M., Miles, Q., Steele, C. D., Munro, C., Baker, A. S., Sheppard, J.-M. E., Frangakis, C., Brandt, J., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.737 · Cited by 398
Research works printed but not linked: 1
- Knapp, 2014, PSSRU Discussion Paper, 2878
Cited by
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
Self-citationRetractedBrain-Derived Neurotrophic Factor in Alzheimer’s Disease and Its Pharmaceutical Potential
Gao, L., Zhang, Y., Sterling, K., & Song, W. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00279-0 · Cited by 606
Safiri, S., Ghaffari Jolfayi, A., Fazlollahi, A., Morsali, S., Sarkesh, A., Daei Sorkhabi, A., Golabi, B., Aletaha, R., Motlagh Asghari, K., Hamidi, S., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1474043 · Cited by 200
New approaches to symptomatic treatments for Alzheimer’s disease
Cummings, J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00424-9 · Cited by 226
Antidepressants for treating depression in dementia
Dudas, R., Malouf, R., McCleery, J., & Dening, T. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003944.pub2 · Cited by 175
Metadata
- Authors
- Orgeta, V., Tabet, N., Nilforooshan, R., & Howard, R.
- Affiliations
- Brighton and Sussex Medical School (GB)
- Corresponding author
- Orgeta, Vasiliki
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2017-06-05
- Volume
- 58
- Issue
- 3
- Pages
- 725-733
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5467718
- OpenAlex
- W2612913686
- Cited by
- 203
- References
- 50
- Citations by year
- 2026: 13 · 2025: 19 · 2024: 29 · 2023: 23 · 2022: 30 · 2021: 30 · 2020: 18 · 2019: 25 · 2018: 15
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Sussex Research Online (University of Sussex) (submittedVersion, cc-by-nc)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by-nc)
- Funders
- Alzheimer's Society
- National Institute for Health and Care Research
- University College London
- University College London Hospitals NHS Foundation Trust
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, depression
- MeSH terms
- Alzheimer Disease, Antidepressive Agents, Depressive Disorder, Humans, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of antidepressants for depression in Alzheimer's disease: systematic review and meta-analysis. https://app.cochat.ai/papers/10.3233/jad-161247
- The paper
- Orgeta, V., Tabet, N., Nilforooshan, R., & Howard, R. (2017). Efficacy of antidepressants for depression in Alzheimer's disease: systematic review and meta-analysis. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-161247
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.